CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER
Chimeric antigen receptors (CARs) which include an antigen binding protein that binds to a discontinuous epitope on human claudin-3 comprising at least N38 and E153 of SEQ ID NO:13 are described. Also described herein includes polynucleotides encoding the antigen binding protein, the CARs, immune effector cells containing the CARs, pharmaceutical compositions containing the immune effector cells, and methods of treating cancer with the immune effector cells.
1 . A chimeric antigen receptor comprising a polypeptide comprising:
a) an extracellular domain which comprises a claudin-3 binding domain comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (CDRH1) sequence of SEQ ID NO: 1; a heavy chain complementarity determining region 2 (CDRH2) sequence of SEQ ID NO: 2; a heavy chain complementarity determining region 3 (CDRH3) sequence of SEQ ID NO: 3;
b) a transmembrane domain; and
c) one or more intracellular signalling domains.
2 . The chimeric antigen receptor according to claim 1 , wherein the extracellular domain further comprises a claudin-3 binding domain comprising a light chain variable region (VL) comprising a light chain complementarity determining region 1 (CDRL1) sequence of SEQ ID NO: 4; a light chain complementarity determining region 2 (CDRL2) sequence of SEQ ID NO: 5; a light chain complementarity determining region 3 (CDRL3) sequence of SEQ ID NO: 6.
3 . The chimeric antigen receptor according to claim 2 , wherein the VL is located at the N-terminus of the VH, or wherein the VH is located at the N-terminus of the VL.
4 . The chimeric antigen receptor according to claim 2 , wherein the VL and the VH are directly fused to each other via a peptide bond or linked to each other via a peptide linker.
5 . The chimeric antigen receptor according to claim 1 , wherein the antigen binding domain is selected from the group consisting of: a Camel Ig, Ig NAR, Fab fragments, Fab′ fragments, F(ab)′2 fragments, F(ab)3 fragments, Fv, single-chain variable fragment (scFv), bis-scFv, (scFv)2, minibody, diabody, triabody, tetrabody, disulfide stabilized Fv protein (dsFv), and single-domain antibody (sdAb).
6 . The chimeric antigen receptor according to claim 1 , wherein the VH comprises an amino acid sequence having at least 90% or 95% sequence identity to SEQ ID NO: 7, or an amino acid sequence having one, two, three, four, or five amino acid substitutions, insertions, or deletions relative to SEQ ID NO: 7, and/or wherein the VL comprises an amino acid sequence having at least 90% or 95% sequence identity to SEQ ID NO: 8, or an amino acid sequence having one, two, three, four, or five amino acid substitutions, insertions, or deletions relative to SEQ ID NO: 8.
7 . The chimeric antigen receptor according to claim 1 , wherein the VH comprises an amino acid sequence of SEQ ID NO: 7 and/or the VL comprises an amino acid sequence of SEQ ID NO: 8.
8 . The chimeric antigen receptor according to claim 1 , wherein the extracellular domain comprises an amino acid sequence having at least 90% or 95% sequence identity to SEQ ID NO: 11, or an amino acid sequence having one, two, three, four, or five amino acid substitutions, insertions, or deletions relative to SEQ ID NO: 11, or wherein the extracellular domain comprises an amino acid sequence having at least 90% or 95% sequence identity to SEQ ID NO: 18, or an amino acid sequence having one, two, three, four, or five amino acid substitutions, insertions, or deletions relative to SEQ ID NO: 18.
9 . The chimeric antigen receptor according to claim 1 , wherein the transmembrane domain is derived from a polypeptide selected from the group consisting of: alpha or beta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137 (4-1BB), CD152, CD154, CD278 (ICOS) and PD1.
10 . The chimeric antigen receptor according to claim 9 , wherein the transmembrane domain is derived from CD8α.
11 . The chimeric antigen receptor according to claim 1 , wherein the one or more intracellular signalling domains is derived from an intracellular signalling molecule selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3ε, CD3δ, CD3ζ, CD22, CD66d, CD79a and CD79b or wherein the one or more intracellular signalling domains is CD3ζ.
12 . The chimeric antigen receptor according to claim 1 , further comprising a co-stimulatory signalling domain.
13 . The chimeric antigen receptor according to claim 12 , wherein the co-stimulatory domain is derived from a co-stimulatory molecule selected from the group consisting of: CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, NKD2C, SLP76, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TRIM and ZAP70.
14 . A chimeric antigen receptor comprising:
a) an extracellular domain which comprises a claudin-3 binding protein comprising a CDRH1 sequence of SEQ ID NO: 1; a CDRH2 sequence of SEQ ID NO: 2; a CDRH3 sequence of SEQ ID NO: 3; a CDRL1 sequence of SEQ ID NO: 4; a CDRL2 sequence of SEQ ID NO: 5; and a CDRL3 sequence of SEQ ID NO: 6;
b) a transmembrane domain derived from CD8α;
c) a costimulatory domain derived from CD137 (4-1BB); and
d) an intracellular signalling domain derived from CD3ζ.
15 . The chimeric antigen receptor according to claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence having at least 90% or 95% sequence identity to SEQ ID NOs: 12, 34, 35, 36, 37, 38, or 39, or an amino acid sequence having one, two, three, four, or five amino acid substitutions, insertions, or deletions relative to SEQ ID NOs: 12, 34, 35, 36, 37, 38, or 39, or wherein the chimeric antigen receptor comprises an amino acid sequence of SEQ ID NOs: 12, 34, 35, 36, 37, 38, or 39.
16 . A chimeric antigen receptor that competes for binding with the chimeric antigen receptor according to claim 1 .
17 . An engineered immune effector cell, comprising the chimeric antigen receptor according to claim 1 .
18 . The immune effector cell according to claim 17 , wherein the immune effector cell is selected from the group consisting of: a T cell, a cytotoxic T lymphocyte, a natural killer T lymphocyte cell, a macrophage, and a natural killer cell.
19 . The immune effector cell according to claim 17 , further comprising an ablation element.
20 . The immune effector cell according to claim 17 , wherein the ablation element is derived from a polypeptide selected from the group consisting of: truncated human EGFR polypeptide and CD20, or wherein the ablation element is CD20.
21 . A polynucleotide encoding the chimeric antigen receptor according to claim 1 .
22 . A vector comprising the polynucleotide of claim 21 .
23 . The vector according to claim 22 , wherein the vector is selected from the group consisting of: retroviral vector, lentiviral vector, adeno-associated virus (AAV) vector, human immunodeficiency virus I (HIV-I), human immunodeficiency virus 2 (HIV-2), visna-maedi virus (VMV) virus, caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immune deficiency virus (BIV), and simian immunodeficiency virus.
24 . A pharmaceutical composition comprising the engineered immune effector cell according to claim 17 , and a pharmaceutically acceptable excipient.
25 . A method of treating cancer in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition according to claim 24 .
26 . The method according to claim 25 , wherein the cancer is solid cancer, epithelial cancer, colorectal cancer, pancreatic cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), or prostate cancer.
27 . The method according to claim 26 , wherein the cancer is colorectal cancer.
28 . A claudin-3 binding protein, comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (CDRH1) sequence of SEQ ID NO: 1; a heavy chain complementarity determining region 2 (CDRH2) sequence of SEQ ID NO: 2; a heavy chain complementarity determining region 3 (CDRH3) sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (CDRL1) sequence of SEQ ID NO: 4; a light chain complementarity determining region 2 (CDRL2) sequence of SEQ ID NO: 5; a light chain complementarity determining region 3 (CDRL3) sequence of SEQ ID NO: 6.
29 . A polynucleotide encoding the claudin-3 binding protein according to claim 28 .
30 . A vector comprising the polynucleotide of claim 29 .
31 . A pharmaceutical composition comprising the claudin-3 binding protein according claim 28 , and a pharmaceutically acceptable excipient.
32 . A method of treating cancer in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition according to claim 31 .
33 . An isolated claudin-3 binding protein that binds to a discontinuous epitope on human claudin-3 comprising at least N38 and E153 of SEQ ID NO:13.
34 . A chimeric antigen receptor comprising a polypeptide comprising:
a) an extracellular domain which comprises the isolated claudin-3 binding protein according to claim 33 ;
b) a transmembrane domain; and
c) one or more intracellular signalling domains.
35 . An engineered immune effector cell, comprising the chimeric antigen receptor according to claim 34 .
36 . A pharmaceutical composition comprising the isolated claudin-3 binding protein according to claim 33 , and a pharmaceutically acceptable excipient.
37 . A method of treating cancer in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition according to claim 36 .